CytomX Therapeutics, Inc. (CTMX) Social Stream
CYTOMX THERAPEUTICS INC (CTMX) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering CYTOMX THERAPEUTICS INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-09 | 7 | $18 | $7 | $12.666 | $1.51 | 738.81% |
| 2021-12-07 | 8 | $18 | $7 | $13.142 | $1.51 | 770.33% |
| 2021-12-22 | 8 | $16 | $7 | $11.714 | $1.51 | 675.76% |
| 2022-01-18 | 8 | $16 | $7 | $12 | $1.51 | 694.7% |
| 2022-02-01 | 7 | $16 | $7 | $11.714 | $1.51 | 675.76% |
| 2022-03-01 | 8 | $16 | $7 | $11.714 | $1.51 | 675.76% |
| 2022-05-05 | 8 | $16 | $7 | $11.571 | $1.51 | 666.29% |
| 2022-05-10 | 8 | $16 | $7 | $11.428 | $1.51 | 656.82% |
| 2022-05-27 | 8 | $16 | $6 | $10 | $1.51 | 562.25% |
| 2022-08-04 | 10 | $8 | $1.5 | $3.953 | $1.51 | 161.79% |
| 2022-08-09 | 10 | $8 | $1.63 | $3.985 | $1.51 | 163.91% |
| 2022-11-09 | 10 | $8 | $1.31 | $3.365 | $1.51 | 122.85% |
| 2023-03-28 | 10 | $8 | $2 | $3.564 | $1.51 | 136.03% |
| 2023-05-10 | 10 | $3.2 | $2 | $2.29 | $1.51 | 51.66% |
| 2023-08-09 | 7 | $3.2 | $2 | $2.29 | $1.51 | 51.66% |
| 2023-08-10 | 7 | $3.19 | $2 | $2.288 | $1.51 | 51.52% |
| 2023-11-08 | 7 | $3.19 | $1.6 | $2.408 | $1.51 | 59.47% |
| 2023-11-20 | 8 | $3.19 | $1.6 | $2.408 | $1.51 | 59.47% |
The Trend in the Analyst Price Target
CTMX's average price target has moved down $10.26 over the prior 25 months.
CTMX reports an average of 74.62% for its upside potential over the past 34 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-03-28 | 10 | 8.00 | 2 | 3.564 | 1.52 | 134.47% |
| 2023-04-05 | 10 | 8.00 | 2 | 3.278 | 1.49 | 120% |
| 2023-05-10 | 10 | 3.20 | 2 | 2.290 | 1.82 | 25.82% |
| 2023-08-09 | 7 | 3.20 | 2 | 2.290 | 1.63 | 40.49% |
| 2023-08-10 | 7 | 3.19 | 2 | 2.288 | 1.71 | 33.8% |
CTMX Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 3.25 | 0 | 0 | 7 | 1 | 1 | 8 |
The Trend in the Broker Recommendations
Over the past 45 months, CTMX's average broker recommendation rating worsened by 1.75.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In terms of how CYTOMX THERAPEUTICS INC fares relative to all US stocks, note that its average analyst price target is greater than 154.08% of that group.
- CYTOMX THERAPEUTICS INC's upside potential (average analyst target price relative to current price) is higher than 1876.78% of all US stocks.
- In the context of stocks in the small market cap category, CYTOMX THERAPEUTICS INC's number of analysts covering the stock is higher than 1984.71% of them.
- In terms of how CYTOMX THERAPEUTICS INC fares relative to stocks in the small market cap category, note that its variance in analysts' estimates is lower than -1643.43% of that group.
In the Pharmaceutical Products industry, WVE, RDHL, and KMDA are the three stocks most similar to CYTOMX THERAPEUTICS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Is CTMX a Buy, Hold or Sell? See the POWR Ratings now!